World leading stem cell research and innovation.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.

 

  • Our research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons (AAOS 2018 Annual Meeting, New Orleans, LA).
  •  
  • Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
  •  
  • Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
  •  
  • Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results.
  •  
  • The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke.
  • The

    Problem

    The

    Solution


    Stem Cell Therapy

    Stem cells are a special kind of cell that can be used to regenerate the human body without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain. BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).

    The

    Opportunity


    FDA endorsed Investigator-led IND (Investigational New Drug) application

    BHI Therapeutic Sciences is initiating FDA endorsed Investigator-led IND (Investigational New Drug) clinical study of an FDA-approved cell therapy (Hematopoietic Progenitor Cell (HPC), cord blood) for treatment of acute ischemic stroke in NJ. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. BHI Therapeutic Sciences is in the process of preparation of Investigator-led IND application to allow for initiation of a clinical study of an FDA-approved cell therapy (HPC, cord blood) for treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intra-articular injection, in subjects with osteoarthritis.

    TEXAS HB 810

    Texas House Bill (HB 810) on stem cell therapy passed in the Texas state legislature and became law, allowing patients suffering from debilitating and incurable diseases to access innovative stem cell therapies and expanded clinical trials.

    BHI Therapeutic Sciences is opening a stem cell treatment facility in Houston, having treated thousands of patients around the world with stem cell therapy.

    Contact BHI Therapeutic Sciences


    BHI Therapeutic Sciences is bringing the miracle of life saving stem cell treatments to the world, and you can help. Thanks to new laws that allow anyone in the general public to invest in new and emerging companies, you can invest in BHI Therapeutic Sciences. Sign up here and be among the first to know of developments with stem cell therapy and the opening of our clinic in Texas.


    BHI Therapeutic Sciences is "testing the waters" for a possible offering of securities under Regulation A of the JOBS act. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind. If an offering statement has been filed, you may obtain a copy of the most recent version of the preliminary offering circular from Kendall Almerico at Kendall A. Almerico PA, 1440 G Street NW, Washington DC 20005 or by e-mailing info@bankroll.ventures.
    Scroll Up